Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session

3416 - Predictive potential of tumour-stroma ratio on benefit from adjuvant bevacizumab in high-risk stage II and stage III colon cancer

Date

09 Sep 2017

Session

Poster display session

Presenters

Stéphanie Zunder

Citation

Annals of Oncology (2017) 28 (suppl_5): v158-v208. 10.1093/annonc/mdx393

Authors

S. Zunder1, G. van Pelt1, H. Gelderblom2, R. Tollenaar3, C. Mancao4, W. Mesker3

Author affiliations

  • 1 Surgery, Leiden University Medical Center (LUMC), 2300 RC - Leiden/NL
  • 2 Medical Oncology, Leiden University Medical Center (LUMC), 2300 RC - Leiden/NL
  • 3 Surgery, Leiden University Medical Center, 2300 RC - Leiden/NL
  • 4 Genentech, F. Hoffmann-La Roche AG - Switzerland, 4070 - Basel/CH
More

Resources

Abstract 3416

Background

The tumour-stroma ratio (TSR) has proven to be an independent prognostic factor in colon cancer.

We evaluated the predictive potential of TSR on disease free survival (DFS) and overall survival (OS) in patients with high-risk stage II and stage III colon cancer who received standard oxaliplatin-based chemotherapy with or without bevacizumab.

Methods

Haematoxylin and Eosin stained tumour slides of 1212 patients (42% of intention-to-treat(ITT)) enrolled in the AVANT trial were microscopically scored for TSR and categorized as stroma-low or stroma-high.

TSR scores were correlated to the primary endpoint DFS and secondary endpoint OS.

Results

Of 1212 tumour slides, 1163 could be scored for TSR. Patients with stroma-high tumours (n = 339) had a significant shorter DFS (p 

Conclusions

Addition of bevacizumab to intravenous oxaliplatin-based chemotherapy suggests, in accordance with AVANT ITT analysis, a pronounced shorter DFS and OS in low stromal tumours. In contrast, in high stromal tumours a (potential) beneficial trend is observed when adding bevacizumab to intravenous oxaliplatin-based chemotherapy.

Clinical trial identification

NCT00112918

Legal entity responsible for the study

Hoffmann-La Roche

Funding

None

Disclosure

H. Gelderblom: Investigational grant institution: Roche. C. Mancao: Employmee of Roche, Genentech stock and other ownership interests; patents, royalties, other intellectual property: Roche/Genentech. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings